BMS's Reblozyl Data Supports Adding Less Severe Patients To Label
Executive Summary
Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.
You may also be interested in...
BMS Forgoes Thalassemia Label Expansion Revenues For Rebozyl
The firm was unable to respond to the US FDA’s questions on Reblozyl’s risk-benefit profile in an expanded beta-thalassemia setting and will now focus label expansion efforts elsewhere.
Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap
The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028.
Acceleron To Be Next M&A Target With Rumored $11bn Deal
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.